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Stem cell-based regenerative therapy is considered a promising cellular therapeutic approach for the patients with incurable
brain diseases. Mesenchymal stem cells (MSCs) represent an attractive cell source for regenerative medicine strategies for the
treatment of the diseased brain. Previous studies have shown that these cells improve behavioral deﬁcits in animal models of
neurological disorders such as Parkinson’s and Huntington’s diseases. In the current study, we examined the capability of
intracerebral human MSCs transplantation (medial pre-frontal cortex) to prevent the social impairment displayed by mice after
withdrawal from daily phencyclidine (PCP) administration (10mgkg
 1 daily for 14 days). Our results show that MSCs
transplantation signiﬁcantly prevented the PCP-induced social deﬁcit, as assessed by the social preference test. In contrast, the
PCP-induced social impairment was not modiﬁed by daily clozapine treatment. Tissue analysis revealed that the human MSCs
survived in the mouse brain throughout the course of the experiment (23 days). Signiﬁcantly increased cortical brain-derived
neurotrophic factor levels were observed in the MSCs-treated group as compared with sham-operated controls. Furthermore,
western blot analysis revealed that the ratio of phosphorylated Akt to Akt was signiﬁcantly elevated in the MSCs-treated mice
compared withthe shamcontrols.Ourresultsdemonstrate thatintracerebral transplantationofMSCs isbeneﬁcial inattenuating
the social deﬁcits induced by sub-chronic PCP administration. We suggest a novel therapeutic approach for the treatment of
schizophrenia-like negative symptoms in animal models of the disorder.
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Introduction
Stem cells research is a rapidly developing ﬁeld with
implications that can revolutionize medicine, promising
remedy to devastating diseases of the brain.
1 Stem cell-
based therapy could exploit one of the two strategies: (i) cell
replacement, when the administered stem cells substitute the
cells lost in a disease. An example for this approach could be
transplantation of functional insulin-producing beta-cells for
diabetes mellitus or dopamine-secreting cells for Parkinson’s
disease. (ii) Cell restoration, when the administered cells
provide a trophic effect, protect, rescue and minimize ongoing
deteriorationofthetissueaffectedinadisease.Anexampleof
this approach would be transplanting cells that provide
neurotrophic support in neurodegenerative diseases.
2
Mesenchymal stem cells (MSCs) hold a potential for
regenerative therapy in neurological diseases.
1,3 Previous
studies have shown that bone marrow MSCs express genes
and proteins associated with the neural lineage, and have
been shown to hold neurogenic differentiation potential
invitro.
4–6Inourlab,wehaveshownthatbraintransplantation
ofMSCsinanimalmodelsofParkinson’sdisease,Huntington’s
disease and multiple sclerosis results in engraftment into the
brain, migration to lesioned sites and, most importantly,
improvement in neuro-behavioral tests.
2,7–12 A single report
has recently described the efﬁcacy of brain MSCs transplan-
tation, also in a rat model of depression.
13 In the aforemen-
tioned studies, though there is no conclusive evidence for the
molecular mechanism underlying the behavioral improve-
ment, it was shown to involve, at least in part, an increase in
the availability of neurotrophic factors.
The complex pathophysiology underlying schizophrenia
(SCZ) has been traditionally related to dysregulation of
dopamine neurotransmission.
14 Additional data suggest that
SCZ is associated with glutamate NMDA receptor dysfunc-
tions.
15 This hypothesis is based on the experimental ﬁnding
that agents that block NMDA receptors such as phencyclidine
(PCP)andMK801induceSCZ-likepsychosis.
16Overthepast
few years, other molecular contributors were implicated in the
disease pathophysiology, such as reduced availability of
neurotrophic factors, speciﬁcally brain-derived neurotrophic
factor (BDNF) in speciﬁc brain regions,
17,18 activation of the
immunesystem,
19impairedneurogenesis,
20oxidativestress
21
and mitochondrial dysfunctions.
22
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www.nature.com/tpModeling SCZ in rodents is a challenge due to the
complexity, the lack of clarity regarding the molecular
processes involved in SCZ and the difﬁculty to relate distinct
behavioral abnormalities in rodents to speciﬁc relevant
symptoms in patients.
23,24 However, in recent years studies
have shown that speciﬁc animal models can be used as tools
to investigate distinct endophenotypes of the disease.
25 Sub-
chronic PCP administration is considered to establish speciﬁc
endophenotypes associated with SCZ,
26 especially the
negative symptoms. Speciﬁcally, social behavior of rodents
treated with PCP is impaired while locomotor activity is
preserved.
27
To date, no study has investigated the application of a stem
cell-basedtherapeuticstrategyinananimalmodelofSCZ-like
behaviors. A single report has indicated the potential of this
approachinaninvitrostudy,usingneuralstemcellstoprotect
cultured neurons against insult induced by a speciﬁc NMDA
receptor antagonist.
28 In the present study, we sought to
conductaproof-of-conceptexperimenttoexplorethepossible
beneﬁt of MSCs transplantation for PCP-induced impaired
social behavior. We transplanted MSCs into the prefrontal
cortex of mice sub-chronically treated with PCP and hypothe-
sized that the engrafted MSCs will prevent or attenuate the
development of PCP-induced impaired social behavior.
Materials and methods
The subacute PCP mouse model. A total of 54 male
C57BL/6 mice aged 6 weeks (Harlan, Jerusalem, Israel)
were used in this experiment. Mice were placed under 12h
light/12h dark conditions and grown in individual ventilated
cages with ad libitum access to food and water. All
experimental protocols were approved by the University
Committee of Animal Use for Research and Education. PCP
(Sigma-Aldrich, St. Lewis, MO, USA; 10mgkg
 1 dissolved
in 0.9% normal saline) was injected subcutaneously daily for
14 days.
Cell culture and Transplantation. Human MSCs were
purchased from the Cambrex Bio Science Walkersville
(Walkersville, MD, USA), cultured and expanded as
previously described.
2 On treatment day, the cells were
harvested, washed and prepared for transplantation at a
concentration of 40000cellsul
 1. Under chloral hydrate
anesthesia, the mice were placed in a digital stereotactic
frame (Stoelting, Wood Dale, IL, USA) and the cells (1ml per
injection site) were injected bilaterally to the following
coordinates (relative to the bregma and dura): anterior–
posterior þ2mm, medial–lateral ±0.4mm, dorsal–ventral
 3.5mm at a rate of 1mlmin
 1 using a Hamilton 701N
syringe (Sigma-Aldrich). The inserted needle was withdrawn
from each location after 5min. Cells viability was assessed at
the end of transplantation session using Trypan blue (Sigma-
Aldrich). For cell tracking purposes, four animals in each
group received injection of cells labeled with the red
ﬂuorescent marker PKH-26 (Sigma-Aldrich).
Experimental design. Transplantation took place at the ﬁrst
day of PCP administration. Sham surgery mice underwent
identical surgical procedure without cells (saline injection
only), clozapine-treated mice received daily clozapine
injections (6mgkg
 1 i.p., from the ﬁrst PCP administration),
daily until the day of testing. The following groups were
evaluated: controls (saline s.c., n¼14), sham surgery PCP
treated (n¼15), MSCs transplanted PCP treated (n¼13),
clozapine and PCP treated (n¼12). In order to prevent
immune response, animals received 15mgkg
 1 s.c.
cyclosporine A (Novartis, Basel, Switzerland) for 3 days
around transplantation. Thereafter, cyclosporine was added
to drinking water (15mgkg
 1 according to expected daily
drinking volume per mouse). Behavioral tests included open-
ﬁeld test conducted 1 day after last PCP administration, and
social preference test was conducted a week after the last
PCP administration. Animals were killed 1 day following the
social preference test. The experimental design is depicted in
Figure 1.
Behavioral tests. Open-ﬁeld test was conducted by
introducing the animals into a 50-cm
2 arena and
videotaping the spontaneous behavior of the mice for
60min. The effects of sub-chronic PCP treatment on social
behavior were assessed using the social preference test,
as previously described.
29 The apparatus was divided into
three compartments (one central and two lateral) containing
two transparent plastic cups with holes placed on either
side of the arena. Before the test day, mice were habituated
for two consecutive days for 20min, during that time the mice
were free to explore the middle chamber. On the test day,
the test mouse was initially habituated to the arena for
10min, during that time two black partitions completely
covered the sides of the arena containing the cups.
Thereafter, the Plexiglas partitions were removed and an
unfamiliar male C57BL/6 mouse was placed in one cup
(social stimulus). The other cup remained empty (inanimate
stimulus). The test mouse was free to explore all the
chambers and was videotaped for another 10min.
Videos were analyzed using the Ethovision 7 software
(Noldus, Wageningen, The Netheralnds), analysis allowed
tracking either the center of the animal or the nose.
Parameters analyzed included total time spent in each
chamber; total nose pokes to the cups and total time in
which the test mouse was in proximity to the cup—as a
representation of social exploration. For calculation of the
behavioral parameters obtained from the social preference
test, we used a preference index, which is calculated
as follows: if time in social chamber is S and time in non
social chamber is NS, then preference index equals to
(S NS)/(SþNS).
Immunohistochemistry. At the end of the experiment (23
days post transplantation), eight animals of each group (four
Figure 1 The study design.
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Translational Psychiatryanimals that were transplanted with the pre-labeled MSCs
and four other randomly selected animals) were anesthetized
with chloral hydrate and transcardially perfused with
cold phosphate-buffered saline, followed by 4%
paraformaldehyde in phosphate buffer. The brains were
then immersed in 4% paraformaldehyde for 24h at 41C
followed by cryoprotection in 30% sucrose for an additional
48h. The brains were frozen in chilled 2-methylbutane
(Sigma-Aldrich), stored at  701C, and subsequently
sectioned to slices measuring 10mM. For microglial
labeling, ﬂuorescein isothiocyanate-conjugated Bandeiraea
simplicifolia isolectin B4 (1:50 in phosphate-buffered saline;
Sigma-Aldrich) was added for 1h. Detection of BDNF was
conducted following 5min antigen retrieval in 5% SDS using
rabbit anti-BDNF antibody (1:200 in blocking solution,
Chemicon/Millipore, Billerica, MA, USA) followed by highly
absorbed goat anti-rabbit Alexa 488 (1:500, Molecular
Probes/Invitrogen, Carlsbad, CA, USA) diluted in
phosphate-buffered saline. Nuclei were counterstained with
40,6-diamidino-2-phenylindole (Sigma-Aldrich). Sections
were mounted with ﬂuorescent mounting solution (Dako,
Glostrup, Denmark), covered with a cover slide and sealed.
Digital images were obtained with a ﬂuorescence Olympus
BX52TF microscope (Olympus, Tokyo, Japan).
Western blot. At the end of the experiment, based on
proximity to the average behavioral data, four animals
from each group were killed using CO2. Immediately
thereafter, crude dissection of the brains was conducted
and whole cortex tissues were separated and cryopreserved
in  701C. Consequently, tissue was thawed and total protein
was produced as previously described.
30 Protein
concentration was determined using BCA kit (Thermo
Scientiﬁc, Rockford, IL, USA). Protein samples underwent
western blot analysis as described previously.
31 Fifty
microgram of protein was loaded in each lane. The
following antibodies were employed: rabbit anti-AKT, rabbit
anti-phospho-AKT (Cell Signaling Technology, Danvers,
MA, USA), anti-ERK (extracellular signal-regulated
kinase), anti-phospho-ERK (Santa Cruz Biotechnology,
Santa Cruz, CA, USA) and anti actin (Millipore).
Visualization and analysis of band intensities were
performed using the Odyssey system (LI-COR, Lincoln,
NE, USA).
ELISA. Quantiﬁcation of BDNF levels was conducted using
a BDNF speciﬁc enzyme-linked immunosorbent assay
(ELISA) kit (Millipore) according to the manufacturer’s
instructions. Protein extracts were loaded on the ELISA
plate (in quadruple samples, 25mg protein in each well). The
absorbance at 450 and 570nm was recorded on a Microplate
Reader (Labsystems, Helsinki, Finland). Results were
normalized to total amount of protein.
Statistics. Data were analyzed using SPSS 17.0. software
(SPSS, Inc., Chicago, IL, USA). Comparisons between
groups were performed with the two-tailed analysis of
variance, with Tukey post hoc test. The results were
considered signiﬁcant at Po0.05. All results are expressed
as mean±s.e.m.
Results
Intra-cortical transplantation of MSCs prevents the
impairment of social preference exhibited in PCP-
treated mice. A day after the last PCP administration,
mice were observed in the open-ﬁeld test and showed
no difference in total locomotor behavior (Supplementary
Figure 1). One week later, mice underwent the social
preference test. In the ﬁrst 10min of the test in which the
mouse was limited to explore the central zone, empty of the
social/non social stimulus, there was no difference in the total
locomotor activity of the mice (as observed by total distance
moved, Figure 2a). However, after 10min, when allowed to
explore both the chambers, that is, the chamber harboring
the social stimulus and the chamber harboring the non-social
stimulus, we found signiﬁcant differences between the
treatment groups in the preference towards the social
stimulus.
Control saline-injected mice showed signiﬁcant
preference towards the social stimulus. In contrast, PCP-
treated mice, which received sham surgery, did not show
signiﬁcant preference for the social stimulus, whereas
the PCP-treated mice transplanted with MSCs showed
signiﬁcant preference towards the social stimulus. Daily
clozapine administration to the PCP-treated mice did not alter
the impaired social preference. Analysis of the social
preference indices revealed that the same patterns of
preference were registered for the total time spent in
chambers (Figure 2b), total number of nose pokes towards
the stimuli (Figure 2c) and total time in close proximity to the
stimuli (Figure 2d).
The transplanted human MSCs survive in the mouse
brain along the experiment without prominent immune
reaction. To evaluate the effect of PCP and the insult of
intra-cortical injection on global inﬂammatory state in the
brain (regardless of cell transplantation), we stained the
sham-treated brains with the ﬂuorescein isothiocyanate-
conjugated microglia marker IB4 and did not detect positive
staining at the end of the experiment (Figure 3a). Upon
analysis of the MSCs-treated mouse brains, we ﬁrst
attempted to locate the transplanted human MSCs.
Fluorescent microscopy analysis revealed that the
transplanted MSCs, pre-labeled with the red ﬂuorescent
dye PKH-26, were detected in the cortex near the site of
transplantation (Figure 3b). We did not ﬁnd any PKH-26-
labeled cells in other brain areas such as the subventricular
zone or the hippocampus. To assess the possibility of
immune rejection in the brains following xenograft
transplantation, we stained the sections harboring the
transplanted cells. Intact PKH-26-positive cells indicated
MSCS survival throughout the experiment. We did detect
some microglia staining overlap the transplanted cells
staining, suggesting that immune response was present
only to some extent (Figures 3c–e).
Increased levels of BDNF in the cortex following MSC
transplantation. Protein lysates of dissected cortical
tissues from PCP-treated mice were analyzed by ELISA.
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Translational PsychiatryWe found 20.53% higher BDNF levels in the cortex of
MSCs-transplanted mice in comparison with mice injected
with saline (Po0.05, Figure 4a). BDNF levels in the
MSCs-treated group was 32.25% (Po0.01) higher
compared with the clozapine-treated group. Of note, no
changes in total BDNF levels were observed in the
hippocampal tissues of the mouse groups (data not
shown). Immunohistochemistry study using anti-BDNF
antibodies in the brain sections revealed that the
transplanted MSCs expressed BDNF. However, the
majority of the BDNF-positive cells were mouse cells
located in the transplanted area (Figures 4b and c).
Figure 3 Immunohistochemistry of cortical brain slices. (a) Green signal is microglia stained with ﬂuorescein isothiocyanate-conjugated IB4 in the brain of mouse treated
with PCPwhounderwentsham transplantation.(b)Red cellsare humanMSCs pre-labeledwith PKH-26.(c–e)Evaluationof rejectionusingmergedphotoof PKH-26-labeled
MSCs and microglia staining. IB4, Bandeiraea simplicifolia isolectin B4; MSCs, mesenchymal stem cells; PCP, phencyclidine.
Figure2 Socialpreferencetest.(a)Totaldistancemovedinthe10minbeforetheexplorationofthelateralcompartmentsharboringthesocialandinanimatestimuli.(b–d)
Preference index calculated in 10min at which the test mouse was free to explore all the chambers. (b) Preference index of time spent in chamber. (c) Preference index of
frequencyofnosepokestothesocialstimulus.(d)Preferenceindexinsocialexploration.Resultsaredisplayedasmeanþs.e.m.Preferenceindexwascalculatedasfollows:
if social is S and non-social is NS, then index¼(S NS)/(SþNS). *Po0.05, **Po0.01. MSCs, mesenchymal stem cells; PCP, phencyclidine.
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Translational PsychiatryMSCs transplantation into the cortex resulted in
increased p-AKT/total AKT ratio. To evaluate the
possible effect of MSCs transplantation on speciﬁc
molecular pathways associated with PCP-induced insult,
we analyzed phosphorylated AKT and ERK levels by western
blot. Analysis of the ratios of phosphorylated ERK to total
ERK (Figure 5b) did not reveal signiﬁcant differences
between the groups. In contrast, we found signiﬁcant
difference in the levels of AKT phosphorylation in the
examined protein lysates of the cortex (Figure 5a), namely,
the percent of phosphorylated-AKT from total AKT was
signiﬁcantly higher in the cortex of the MSCs-treated mice as
compared with the PCP sham surgery group (1.85-fold,
Po0.05). AKT phosphorylation ratio in MSCs-treated group
Figure 4 BDNF levels in the cortex. (a) Quantiﬁcation of BDNF levels using ELISA, results represent picogram BDNF measured normalized to milligram cortex tissue
(*Po0.05, **Po0.01). (b, c) Immunohistochemistry against BDNF in cortical brain slices of mice transplanted with MSCs (red, PKH pre-labeled human cells; green, BDNF
signal; yellow, merge). BDNF, brain-derived neurotrophic factor; ELISA, enzyme-linked immunosorbent assay; MSCs, mesenchymal stem cells; PCP, phencyclidine.
Figure 5 Western blot analysis of phosphorylated AKT (a) and ERK (b) in cortical lysates. Results represent ratio of phosphorylated protein to total protein—each was
normalized to actin. The ratio obtained in untreated controls (saline instead of PCP (phencyclidine) and no cell/clozapine treatment) is represented as 100%. *Po0.05,
**Po0.01.
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Translational Psychiatrywas also signiﬁcantly higher compared with the PCP-
clozapine group (3.82-fold, Po0.01).
Discussion
In this study, we present a novel approach for the treatment
of an animal model of SCZ-like social impairment. In the
current proof-of-concept study, we speciﬁcally show that the
social deﬁcit behavior induced by sub-chronic administration
of PCP can be prevented by intra-cortical transplantation of
MSCs, at variance from clozapine that failed to prevent the
social deﬁcit. The notion of applying MSCs-based therapeutic
approach to an animal model of SCZ stems from the two
complementing details: (1) the frustrating deadlock of
antipsychotics in the treatment of negative symptoms of
SCZ.
32 (2) The accumulating body of evidence suggesting
the beneﬁt of MSCs-based therapeutic strategies for brain
diseases.
33,34
Current treatments for SCZ are aimed mainly at antagoniz-
ing dopamine and other neurotransmitter receptors, and yield
relatively limited success in the treatment of SCZ-related
negative symptoms and cognitive deﬁcits. Importantly,
current antipsychotic medications rely upon the rationale of
over-active dopaminergic activity or other dysregulated
neurotransmitter systems in the brain. Therefore, antipsycho-
tics are efﬁcient in controlling the positive symptoms, which
are strongly associated with post-synaptic monoamine
receptors over-activity.
14 Recent studies suggest that the
pathophysiology underlying SCZ may also involves pro-
cesses associated with neurodegeneration.
21,22,35–37 For
these aspects of the disease, current antipsychotic therapy
offers limited resolution. Intra-brain MSCs transplantation has
been shown to inﬂuence speciﬁc processes relevant to the
pathophysiology of neuropsychiatric diseases. Those include
the effect of MSCs on the (i) brain immune status,
38 (ii)
neurotrophic factor availability
39,40 and (iii) neurogenesis.
41,42
Designing the study, we sought to utilize one of the most
established rodent model of SCZ-negative symptoms,
namely, the subacute PCP model.
43 We chose the social
preference test as it presents a relatively straightforward
paradigm of measuring sociability and was recently validated
in C57/BL mice.
27 We performed cell transplantation con-
comitantly with the ﬁrst dose of PCP, aiming to provide the
transplanted cells the optimal chances of protection against
the iatrogenic insult. Transplantation was aimed at the
anatomical site, which is assumed to be involved in the social
insult induced by the PCP, namely, the prefrontal cortex.
44,45
We included clozapine-treated mice as a comparator group
owing to a report which had shown that clozapine treatment
could reverse some of the social deﬁcits induced by sub-
chronic PCP treatment.
46 The fact that clozapine did not
reversethesocialdeﬁcitsinourstudymaybeexplainedbythe
differences in the behavioral test, the mouse strain or the
treatment regimen employed in our study.
We chose to transplant human MSCs as they are more
readily cultured, better characterized, not tumorogenic and
not contaminated by hematopoietic cells in comparison with
mouse-derivedMSCs.
47Importantly,our previousexperience
with transplantation into various models of neurodegenerative
diseases has shown that human MSCs survive in the brain
and exert some beneﬁcial effects.
2,8,10 This choice faced us
with the challenge of immune rejection and the need to use
cyclosporine. In order to minimize the possible effects of
cyclosporineonthesocialbehavior,
48 allthegroups,including
the control, received identical cyclosporine treatment. Evi-
dently, the intensity of immunosuppression we employed was
sufﬁcient to allow the human MSCs to survive in the brain
along the whole experiment period, 23 days, with only limited
immune rejection.
The behavioral results of the social preference test seemed
to conﬁrm our hypothesis that MSCs could act to protect
against the social deﬁcit induced by the PCP administration.
As it is known that MSCs modulate immune response in the
CNS,
38 we ﬁrst evaluated whether an immune process/
inﬂammation occurred following the PCP insult. To that end,
we used the staining for microglia and found that no
inﬂammation was present in the brains following the PCP
treatment.
Neurotrophic factor availability, speciﬁcally BDNF, is
postulated to have a key role in many aspects of brain
development, maintenance and function, including the for-
mation of synapses and neural circuits.
49,50 Several studies
haveshownthat dysregulation ofBDNF expressionin speciﬁc
brain regions may be involved in the pathophysiology of
various neuropsychiatric disorders, including SCZ.
51,52 Of
note, BDNF has emerged as a key factor in the development
and maintenance of social behavior.
53,54 Importantly, BDNF
mRNA levels were recently reported to be downregulated in
the prefrontal cortex of female rats sub-chronically treated
with PCP.
55 MSCs are known to enhance neurotrophic factor
availability,eitherbydirectsecretionbytheengraftedcells
2or
by enhancement of endogenous levels through in situ
interaction with the host brain cells.
40 On the basis of the
above mentioned data, we postulated that transplantation of
MSCs into the cortex of mice sub-chronically treated with
PCP, could increase BDNF levels adjacent to the transplanta-
tion site, and counteract some of the negative behavioral
effects of the PCP. Notwithstanding, we cannot rule out that
other soluble factors that are increased following administra-
tion of MSCs could also be involved in the positive behavioral
outcome of MSCs intra-cortical transplantation.
56
Quantitative ELISA analysis of BDNF levels in the cortex
extracts of PCP-injected mice indeed demonstrated higher
BDNF levels in the MSCs-treated group compared with the
sham-operated or clozapine-treated groups. The relatively
low number of transplanted cells (only 40000cells per cortex)
together with the immunohistochemical analysis of BDNF
implies that although some BDNF was secreted from the
transplanted human MSCs, most BDNF originated from the
endogenous mouse brain cells. This explanation is in context
with a recent report in a stroke rat model that has shown that
MSCs transplantation induces a therapeutic response
through the induction of the host astrocytes to upregulate
the levels of neurotrophic factors.
40
Recently it was shown that, in vitro, acute exposure of
neurons to PCP results in rapid death through apoptosis.
57
Importantly, this study has demonstrated that the insult
induced by PCP could be prevented following the addition
of recombinant BDNF. It was suggested that the protective
effect of BDNF is associated with the activation of the
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Translational Psychiatryphosphatidylinositol 3-kinase/AKT and the ERK pathways.
Interestingly, the only report to date to examine stem cell
protective effect on cultured neurons following NMDA
receptor blockade showed that the protection occurs via
AKT/ERK signal regulation.
28 Our data show that MSCs
transplantation results in higher phosphorylated AKT/total
AKT ratio as compared with the sham-operated or clozapine-
treatedmice.Wecouldnotdetectsigniﬁcantdifferencesinthe
phosphorylated ERK ratios or in the total levels of cleaved
caspase (data not shown). This could be explained by the fact
thatwekilled theanimals10daysfollowingthe lastPCP dose,
while the in vitro study mentioned above showed that PCP-
induced apoptosis occurs within hours after the exposure.
57
Our study serves as a pioneer proof-of-concept for cell-
based therapeutic strategies for SCZ animal models. To our
knowledge, this is the ﬁrst report of stem cell transplantation
study in an animal model of SCZ. Evidently, future studies
would have to face the challenge of enlarging the battery of
behavioral tests representing several SCZ-related endophe-
notypes/dimensions. We have shown that MSCs transplanta-
tion can protect against the PCP insult, however, future
studies should be performed in an attempt to explore the
possibilityofreversinganalreadyestablisheddamage(thatis,
transplantcellsafterthelastPCPdose),ortotryandusestem
cell-based approaches in relevant transgenic mouse models
of SCZ. Another prospect that would have to be explored in
the future is the optimal site of transplantation, that is,
evaluation of effects of MSCs in other brain sites affected in
SCZ and PCP abuse, such as the hippocampus.
To conclude, we showed that intra-cortical MSCs trans-
plantation protected against the social deﬁcit induced by sub-
chronic PCP administration. Analysis of the mouse brains
showed higher levels of BDNF in the MSCs-treated mouse
cortex and elevated ration of p-AKT/AKT compared with the
sham-treated controls. Interestingly, BDNF and p-AKT were
recently reported to protect neuronal culture against PCP
insult in vitro. Our study suggests that MSCs transplantation
might be considered, at least at the experimental laboratory
level, as a putative strategy for the treatment of some SCZ-
related endophenotypes/dimensions, such as negative symp-
toms and cognitive deﬁcits.
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